Attached files
file | filename |
---|---|
8-K - FORM 8-K - Lexaria Bioscience Corp. | form8k.htm |
Exhibit 99.1
CEO Clips Features Lexaria on the BNN Channel
Kelowna, BC / January 31, 2017 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the Company) is currently being featured on CEO Clips
airing on BNN. CEO Clips profiles some of the most innovative publicly traded
companies in North America and is currently featuring a 15 second clip about
Lexaria. The clip can also be viewed online via this link:
http://www.b-tv.com/lexaria-commercial/
BTV has also produced a CEO clip with Company President John Docherty introducing Lexarias technology. The clip can be viewed at http://www.b-tv.com/lexaria-ceo-clip/ and has also been posted on the Thomson Reuters Insider Network where it can be viewed by over 80,000 financial professionals at http://reut.rs/2kc0Ewn
Lexaria has separately engaged SJF Communications for a 3-month social media campaign designed to distribute Lexaria information to as wide a network as possible. SJF Communications owns @CanadaPotStocks and is a top influencer with over 18,000 followers on Twitter and is considered a leading source for information & opportunity in the emerging legal cannabis sector.
Lexarias unique patented technology allows for more efficient and effective absorption of certain molecules such as cannabinoids, while simultaneously masking and at times even eliminating inherent strong flavours and/or odors typical of those molecules. Lexarias technology is extremely cost effective to implement and applicable to the widest imaginable spectrum of foods.
About Lexaria
Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Companys lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Companys
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. www.lexariabioscience.com
About BNN
Business News Network (BNN) is Canada's only all
business specialty channel with real time coverage of global market activity
from a Canadian perspective.
FOR FURTHER INFORMATION PLEASE CONTACT: |
Lexaria Bioscience Corp. |
Chris Bunka |
Chairman & CEO |
(250) 765-6424 |
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, the patent application and approval process and other factors which
may be identified from time to time in the Company's public announcements and
filings. There is no assurance that the recent license agreement, hemp oil
sector, or alternative health businesses will provide any benefit to Lexaria, or
that the Company will experience any growth through participation in these
sectors or as a result of the license agreement. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements, nor that Lexarias technology will deliver any improvement in taste
or bioavailability with any reliability nor across any product category. There
is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexarias postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.